Translate Bio Inc (NASDAQ:TBIO)’s share price traded up 8.9% during mid-day trading on Wednesday . The company traded as high as $8.58 and last traded at $8.55, 332,258 shares traded hands during trading. An increase of 12% from the average session volume of 297,266 shares. The stock had previously closed at $7.85.

TBIO has been the subject of several analyst reports. Zacks Investment Research raised shares of Translate Bio from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Friday, January 10th. ValuEngine downgraded shares of Translate Bio from a “hold” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Translate Bio has an average rating of “Buy” and a consensus price target of $18.80.

The company has a debt-to-equity ratio of 0.62, a current ratio of 8.62 and a quick ratio of 8.62. The stock has a market capitalization of $482.58 million, a PE ratio of -2.21 and a beta of 0.81. The stock has a 50 day moving average of $8.58 and a two-hundred day moving average of $9.22.

Translate Bio (NASDAQ:TBIO) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.04. The firm had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.77 million. Translate Bio had a negative return on equity of 59.18% and a negative net margin of 1,732.61%. As a group, research analysts predict that Translate Bio Inc will post -1.56 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the business. Alpine Global Management LLC acquired a new position in shares of Translate Bio during the 4th quarter worth $266,000. Squarepoint Ops LLC acquired a new stake in shares of Translate Bio in the third quarter valued at about $128,000. State Street Corp boosted its holdings in Translate Bio by 12.7% during the third quarter. State Street Corp now owns 563,057 shares of the company’s stock worth $5,580,000 after buying an additional 63,425 shares in the last quarter. First Allied Advisory Services Inc. purchased a new stake in Translate Bio during the third quarter worth about $129,000. Finally, Gamco Investors INC. ET AL purchased a new stake in Translate Bio during the third quarter worth about $99,000. 87.71% of the stock is owned by institutional investors.

Translate Bio Company Profile (NASDAQ:TBIO)

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Recommended Story: VIX – Volatility Index

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with's FREE daily email newsletter.